Sunshine, Sara
Puschnik, Andreas S. http://orcid.org/0000-0002-9605-9458
Replogle, Joseph M. http://orcid.org/0000-0003-1832-919X
Laurie, Matthew T.
Liu, Jamin http://orcid.org/0000-0001-6386-3709
Zha, Beth Shoshana http://orcid.org/0000-0002-4190-2823
Nuñez, James K.
Byrum, Janie R.
McMorrow, Aidan H.
Frieman, Matthew B. http://orcid.org/0000-0003-0107-0775
Winkler, Juliane http://orcid.org/0000-0002-9762-1721
Qiu, Xiaojie
Rosenberg, Oren S. http://orcid.org/0000-0002-5736-4388
Leonetti, Manuel D. http://orcid.org/0000-0002-4881-405X
Ye, Chun Jimmie http://orcid.org/0000-0001-6560-3783
Weissman, Jonathan S. http://orcid.org/0000-0003-2445-670X
DeRisi, Joseph L.
Hein, Marco Y. http://orcid.org/0000-0002-9490-2261
Funding for this research was provided by:
United States Department of Defense | Defense Advanced Research Projects Agency (HR0011-19-2-2007)
Article History
Received: 30 May 2023
Accepted: 15 September 2023
First Online: 6 October 2023
Competing interests
: J.L.D. is a paid scientific advisor for Allen & Co. J.L.D. is a paid scientific advisor for the Public Health Company, Inc. and holds stock options. J.L.D. is a founder and holds stock options for VeriPhi Health, Inc. J.S.W. declares outside interest in 5 AM Ventures, Amgen, Chroma Medicine, KSQ Therapeutics, Maze Therapeutics, Tenaya Therapeutics, Tessera Therapeutics, and Third Rock Ventures. J.S.W. is an inventor on US Patent 11,254,933, related to CRISPRi screening, and has filed patents related to Perturb-seq that do not restrict academic use. M.Y.H. is a consultant for Illumina, Inc. J.M.R. is a consultant for Maze Therapeutics and Waypoint Bio. The remaining authors declare no competing interests.